Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

Scott Antonia(Moffitt Cancer Center), Sarah B. Goldberg(Yale Cancer Center), Ani Sarkis Balmanoukian(Angeles Clinic and Research Institute), Jamie E. Chaft(Memorial Sloan Kettering Cancer Center), Rachel E. Sanborn(Providence Portland Medical Center), Ashok Gupta, Rajesh Narwal, Keith E. Steele, Yu Gu, Joyson Karakunnel, Naiyer A. Rizvi(Columbia University Irving Medical Center)
The Lancet Oncology
February 5, 2016
Cited by 594Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis